Ireland - English - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - phenylpropanolamine hydrochloride - syrup - 50 milligram(s)/millilitre - phenylpropanolamin

Ireland - English - HPRA (Health Products Regulatory Authority)

fatro s.p.a. - phenylpropanolamine hydrochloride - syrup - 40 milligram(s)/millilitre - phenylpropanolamin

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - purified water; sucrose - oral solution - 333mg/1gram ; 667mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

optima consumer health ltd - purified water; sucrose - oral solution - 333mg/1gram ; 667mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - purified water; sucrose - oral solution - 333mg/1gram ; 667mg/1gram

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: sorbitol; sodium propyl hydroxybenzoate; sodium methyl hydroxybenzoate; saccharin sodium; brilliant scarlet 4r; purified water; sucrose; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - chlorpromazine hydrochloride, quantity: 5 mg/ml - oral liquid - excipient ingredients: sucrose; caramel; peppermint oil; spearmint oil; polysorbate 20; purified water; citric acid; sodium citrate dihydrate; ascorbic acid; sodium sulfite; sodium metabisulfite; sodium benzoate; flavour - 1. treatment of acute functional psychosis (eg schizophrenia, mania or psychotic depression). 2. long-term treatment of schizophrenia. 3. short-term treatment of agitation and severe depression. 4. severe behavioural disturbances, as can be found in some children with mental retardation or autism, including the treatment of self-injurious and aggressive behaviour or overactivity. use of chlorpromazine should be in conjunction with an appropriate non-pharmacological management program and long-term use should only be carried out under the supervision of a physician experienced in the management of psychotic disorders in children. 5. in the management of terminal illness to enhance the effect of analgesics and to control nausea and vomiting. 6. control of intractable hiccough.

Ireland - English - HPRA (Health Products Regulatory Authority)

ucb (pharma) ireland limited - hydroxyzine hydrochloride - syrup - 10 mg/5ml

Austria - English - HMA (Heads of Medicines Agencies)

dechra limited - phenylpropanolamine hydrochloride 50 mg/ml - syrup - dogs - phenylpropanolamin

Greece - English - HMA (Heads of Medicines Agencies)

dechra limited - phenylpropanolamine hydrochloride 50 mg/ml - syrup - dogs - phenylpropanolamin